The company posted Q4 revenues of $10.9 million, up from $6.6 million in Q4 2017, beating the consensus Wall Street estimate of $9.3 million.
According to researchers, measurement of serum neurofilament light chain levels could aid in early diagnosis and monitoring of the progression of disease.
The company posted Q3 revenues of $10.6 million, up from $5.7 million in Q3 2017 and beating the consensus Wall Street estimate of $8.5 million.
Called CerMark, the test is aimed at women in resource-constrained settings and will measure proteins linked to HPV infection and cervical disease progression.
The firm is developing tests combining biomarkers and other clinical measures to diagnose and monitor patients and identify those at risk of long-term effects.
By ending the agreement, Quanterix regains full control over its Simoa immunoassay technology and its potential use for in vitro diagnostic purposes.
The platform counts single target molecules in stool samples within 30 minutes and without sample preparation to detect C. diff. toxins.
The company posted Q1 revenues of $7.5 million, up from $5.3 million in Q1 2017 and above the consensus Wall Street estimate of $7.1 million.
Neurofilament light protein may be able to determine when an athlete who's suffered a concussion can safely return to playing again, researchers said.
The effort will use Quanterix's Simoa technology and will focus initially on development of an assay for measuring the liver toxicity biomarker microRNA-122.